Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 24, Issue 1, 2009, Pages 316-320

  Helanterä, Ilkka ^a   Lautenschlager, Irmeli ^a   Koskinen, Petri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cytomegalovirus (CMV); Kidney transplantation; Valganciclovir

Indexed keywords

VALGANCICLOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY GRAFT; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FINLAND; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE DONORS;

EID: 58049209806     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn558     Document Type: Article

References (22)

1. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-337
2. Helantera I, Koskinen P, Finne P et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19: 893-900
3. Grattan MT, Moreno-Cabral CE, Starnes VA et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566
4. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174
5. Preiksaitis JK, Brennan DC, Fishman J et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-227
6. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620
7. Akalin E, Sehgal V, Ames S et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731-735
8. Kliem V, Fricke L, Wollbrink T et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983
9. Doyle AM, Warburton KM, Goral S et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106-1111
10. Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846
11. Eid AJ, Arthurs SK, Deziel PJ et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22: 162-170
12. Piiparinen H, Hockerstedt K, Gronhagen-Riska C et al. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004; 30: 258-266
13. Levey AS, Greene T, Kusek JW et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 115 (abstract)
14. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979
15. Steininger C, Kundi M, Kletzmayr J et al. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908-1912
16. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16: 281-287
17. Freeman RB, Paya C, Pescovitz MD et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78: 1765-1773
18. Humar A, Mazzulli T, Moussa G et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients. Am J Transplant 2005; 5: 1065-1070
19. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143
20. Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13: 1703-1709
21. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant 2007; 26: 1019-1024
22. Razonable RR, Brown RA, Wilson J et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002; 73: 968-973